Expansion of Global Sales and Service Infrastructure and Solution Proposals
First written in FY2016. 24 of 32 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2026.
- FY2026Updated full-year overseas sales performanceAnnual report
「In overseas sales, sales of reagents and other products in the blood coagulation testing field declined. Meanwhile, sales of instruments and reagents in the urinalysis and other fields, and reagent sales in the hematology field, increased. As a result, overseas sales were ¥441,403 million, up 0.1% from the previous fiscal year, and accounted for 88.3% of total sales, up 1.6 percentage points from the previous fiscal year.」
In overseas sales, sales of blood coagulation testing reagents and other products declined, while instruments and reagents in the urinalysis and other fields and hematology reagents increased. Full-year overseas sales rose 0.1% from the previous fiscal year. - FY2026-H1Updated first-half overseas sales resultsAnnual report
「In overseas sales, sales of equipment, reagents and maintenance services in the hematology field declined, and the yen remained strong against other currencies. As a result, overseas sales totaled ¥207,092 million, down 2.4% year on year, accounting for 89.1% of sales, up 1.6 percentage points year on year.」
Overseas sales of hematology instruments, reagents and maintenance services declined, and the stronger yen also contributed to a 2.4% year-on-year decrease in first-half overseas sales. - FY2024AdvancedAnnual report
「In Italy, in addition to the life sciences and other fields in which we had previously provided direct sales and services, we began providing direct sales and services in the hematology, urinalysis and blood coagulation testing fields from April 2024. We aim to expand our business in Italy by promoting market share growth in each testing field and proposing solutions to the diverse challenges faced by medical institutions through direct communication with customers.」
In Italy, direct sales and services were expanded to 3 fields: hematology, urinalysis and blood coagulation, beginning in April 2024. - FY2024-Q2AdvancedAnnual report
「Overseas sales increased as sales of hematology instruments, reagents and maintenance services rose, while the yen remained weak against other currencies. Overseas sales were ¥185,030 million, up 12.0% year on year, and accounted for 87.0% of total sales, up 1.9 percentage points year on year.」
Cumulative overseas sales for the first 2 quarters increased 12.0% year on year, due to higher sales of hematology instruments, reagents and maintenance services. - FY2024-Q1AdvancedAnnual report
「In overseas sales, sales of reagents and maintenance services in the hematology field and reagents in the urinalysis field increased. In addition, the yen remained weak against other currencies. As a result, overseas sales totaled ¥82,315 million, up 12.7% year on year, accounting for 86.3% of sales, up 1.4 percentage points year on year.」
As a result of initiatives concerning the overseas sales and service structure, overseas sales increased 12.7% year on year, driven by higher sales of hematology reagents and maintenance services and urinalysis reagents. - FY2023AdvancedAnnual report
「In overseas sales, the group was affected by the spread of COVID-19 in the previous fiscal year. However, as demand for testing recovered, reagent sales increased mainly in the hematology, urinalysis and blood coagulation testing fields. In addition, the yen remained weak against other currencies. As a result, the group's overseas sales were ¥350,669 million, up 13.8% from the previous fiscal year, and accounted for 85.4% of total sales, up 0.7 percentage points from the previous fiscal year.」
Against a backdrop of recovering demand for testing, higher reagent sales in key fields, and the weaker yen, full-year overseas sales increased 13.8% from the previous fiscal year. - FY2023-Q3AdvancedAnnual report
「In overseas sales, although the same period of the previous year was affected by the spread of COVID-19, reagent sales increased mainly in the hematology, urinalysis and blood coagulation testing fields as testing demand recovered. In addition, the yen remained weak against other currencies. As a result, the Group's overseas sales totaled ¥254,978 million, up 16.1% year on year, accounting for 85.4% of sales, up 0.5 percentage points year on year.」
Cumulative overseas sales for the first 3 quarters increased 16.1% year on year, against a backdrop of recovering demand for testing, higher reagent sales in the hematology, urinalysis and blood coagulation fields, and the weaker yen. - FY2023-Q2AdvancedAnnual report
「In overseas sales, although the same period of the previous year was affected by the spread of COVID-19, reagent sales increased mainly in the hematology, urinalysis and blood coagulation testing fields as testing demand recovered. In addition, the yen remained weak against other currencies. As a result, the Group's overseas sales totaled ¥165,229 million, up 15.4% year on year, accounting for 85.1% of sales, up 0.1 percentage points year on year.」
Cumulative overseas sales for the first 2 quarters increased 15.4% year on year, due to recovering demand for testing and higher reagent sales in the hematology, urinalysis and blood coagulation fields, among other factors. - FY2023-Q1AdvancedAnnual report
「In overseas sales, although the same period of the previous year was affected by the spread of COVID-19, reagent sales increased mainly in the hematology, urinalysis and blood coagulation testing fields as testing demand recovered. In addition, the yen remained weak against other currencies. As a result, the Group's overseas sales totaled ¥73,065 million, up 8.8% year on year, accounting for 84.9% of sales, up 0.3 percentage points year on year.」
Overseas sales increased 8.8% year on year, mainly due to higher reagent sales in the hematology, urinalysis and blood coagulation fields as demand for testing recovered. - FY2022AdvancedAnnual report
「In overseas sales, the group was affected by the spread of COVID-19 in the same period of the previous year. However, as demand for testing recovered, reagent sales increased mainly in the hematology, urinalysis and blood coagulation testing fields. In addition, the yen remained weak against other currencies. As a result, the group's overseas sales were ¥308,161 million, up 20.2% from the previous fiscal year, and accounted for 84.7% of total sales, up 0.7 percentage points from the previous fiscal year.」
Against a backdrop of recovering demand for testing, higher reagent sales in the hematology, urinalysis and blood coagulation fields, and the weaker yen, overseas sales rose 20.2% from the previous fiscal year. - FY2022-Q3AdvancedAnnual report
「In overseas sales, although the same period of the previous year was affected by the spread of COVID-19, reagent sales increased mainly in the hematology and urinalysis fields as testing demand recovered. In addition, the yen remained weak against other currencies. As a result, the Group's overseas sales totaled ¥219,618 million, up 23.0% year on year, accounting for 84.9% of sales, up 0.6 percentage points year on year.」
Against a backdrop of recovering demand for testing, higher reagent sales in the hematology and urinalysis fields, and the weaker yen, overseas sales increased 23.0% year on year. - FY2022-Q2AdvancedAnnual report
「In overseas sales, the group was affected by the spread of COVID-19 in the same period of the previous year. However, as demand for testing recovered, reagent sales increased mainly in the hematology and urinalysis fields. In addition, the yen remained weak against other currencies. As a result, the group's overseas sales were ¥143,196 million, up 29.2% year on year, and accounted for 85.0% of total sales, up 1.1 percentage points year on year.」
Against a backdrop of recovering demand for testing, higher reagent sales in the hematology and urinalysis fields, and the weaker yen, overseas sales rose 29.2% year on year and accounted for 85.0% of total sales. - FY2022-Q1AdvancedAnnual report
「In overseas sales, the group was affected by the spread of COVID-19 in the same period of the previous year. However, as demand for testing recovered, reagent sales increased mainly in the hematology and urinalysis fields. In addition, the yen remained weak against other currencies. As a result, the group's overseas sales were ¥67,136 million, up 31.3% year on year, and accounted for 84.6% of total sales, up 0.1 percentage points year on year.」
As demand for testing recovered from the impact of COVID-19 in the same period of the previous year, reagent sales increased in the hematology and urinalysis fields, and the weaker yen also contributed to a 31.3% year-on-year increase in overseas sales. - FY2021Updated full-year overseas sales resultsAnnual report
「Overseas sales of reagents declined, mainly in the hematology and urinalysis fields, due to the impact of the spread of COVID-19, while sales of instruments increased in the urinalysis, blood coagulation testing and immunoassay fields. As a result, overseas sales were ¥256,316 million, up 0.4% year on year, and accounted for 84.0% of total sales, down 0.5 percentage points year on year.」
Reagent sales in the hematology and urinalysis fields declined due to the impact of COVID-19, while instrument sales in the urinalysis, blood coagulation and immunoassay fields increased, resulting in a slight increase in overseas sales. - FY2021-Q3Updated cumulative third-quarter overseas sales performanceAnnual report
「In overseas sales, equipment sales increased in the urinalysis, blood coagulation testing and immunochemistry testing fields, but reagent sales declined mainly in the hematology, urinalysis and immunochemistry testing fields, primarily due to the impact of the spread of COVID-19. As a result, the Group's overseas sales totaled ¥178,553 million, down 3.0% year on year, accounting for 84.3% of sales, down 0.1 percentage points year on year.」
Although equipment sales increased in some testing fields, reagent sales declined in multiple fields due to the impact of COVID-19, resulting in a 3.0% year-on-year decline in overseas sales. - FY2021-Q2Overseas sales performance declined due to the impact of COVID-19Annual report
「In overseas sales, equipment sales increased in the urinalysis, blood coagulation testing and immunochemistry testing fields, but reagent sales declined mainly in the hematology, urinalysis and immunochemistry testing fields, primarily due to the impact of the spread of COVID-19. As a result, the Group's overseas sales totaled ¥110,807 million, down 7.9% year on year, accounting for 83.9% of sales, down 0.2 percentage points year on year.」
Although equipment sales increased in some fields, reagent sales declined in multiple fields due to the impact of COVID-19, resulting in a 7.9% year-on-year decline in overseas sales. - FY2020AdvancedAnnual report
「In overseas sales, reagent sales declined mainly in the blood coagulation testing field, while reagent sales grew in the hematology testing field. As a result, overseas sales totaled ¥255,255 million, up 2.3% from the previous fiscal year, accounting for 84.5% of sales, down 0.5 percentage points from the previous fiscal year.」
In overseas sales, reagent sales declined in the blood coagulation field, while reagent sales grew in the hematology field, resulting in a 2.3% increase in overseas sales from the previous fiscal year. - FY2020-Q3AdvancedAnnual report
「In overseas sales, although reagent sales declined mainly in the blood coagulation testing field, reagent sales grew mainly in the hematology, urinalysis and immunochemistry testing fields. As a result, the Group's overseas sales totaled ¥184,167 million, up 4.3% year on year, accounting for 84.4% of sales, down 0.3 percentage points year on year.」
In overseas sales, reagent sales declined in the blood coagulation testing field, while reagent sales grew mainly in the hematology, urinalysis and immunochemistry testing fields, resulting in a 4.3% year-on-year increase in cumulative third-quarter overseas sales. - FY2020-Q2AdvancedAnnual report
「In overseas sales, reagent sales declined mainly in the blood coagulation testing field, but increased in the hematology, urinalysis and immunoassay fields. As a result, the Group’s overseas sales were ¥120,298 million, up 4.4% year on year, and accounted for 84.1% of sales, down 0.5 percentage points year on year.」
Growth in reagent sales mainly in the hematology, urinalysis and immunochemistry testing fields resulted in a 4.4% year-on-year increase in cumulative second-quarter overseas sales. Meanwhile, reagent sales declined in the blood coagulation testing field. - FY2020-Q1AdvancedAnnual report
「In overseas sales, although reagent sales declined mainly in the blood coagulation testing field, reagent sales grew mainly in the hematology, urinalysis and immunochemistry testing fields. As a result, the Group's overseas sales totaled ¥58,399 million, up 3.5% year on year, accounting for 85.2% of sales, down 0.3 percentage points year on year.」
In overseas sales, reagent sales declined in the blood coagulation testing field, while reagent sales grew mainly in the hematology, urinalysis and immunochemistry testing fields, resulting in a 3.5% year-on-year increase in overseas sales. - FY2019-Q3AdvancedAnnual report
「In overseas sales, although equipment sales declined mainly in the hematology testing field, reagent sales grew in the hematology, blood coagulation testing and immunochemistry testing fields. As a result, overseas sales totaled ¥176,548 million, up 3.7% year on year, accounting for 84.7% of sales, up 0.6 percentage points year on year.」
In overseas sales, reagent sales grew in the hematology, blood coagulation and immunochemistry testing fields, and cumulative third-quarter overseas sales increased 3.7% year on year. Meanwhile, equipment sales declined in the hematology testing field. - FY2019-Q2AdvancedAnnual report
「As the business expanded in North America, comprising the United States and Canada, we consolidated and expanded training functions for customers and our own technical staff at a single location and opened a new support center in the United States in July 2018. The facility has 7 studios dedicated to virtual training, more than triple the previous number, enabling us to provide faster and more efficient training services so that more customers can use our products with confidence.」
A new support center consolidating training functions was opened in North America in July 2018, with 7 studios dedicated to virtual training, more than triple the previous number. - FY2019-Q1AdvancedAnnual report
「In overseas sales, although equipment sales declined, reagent sales grew mainly in the hematology, blood coagulation testing and immunochemistry testing fields. As a result, the Group's overseas sales totaled ¥56,398 million, up 7.8% year on year, accounting for 85.5% of sales, up 0.7 percentage points year on year.」
The company discloses concrete results, including growth in reagent sales in the hematology, blood coagulation testing and immunochemistry testing fields despite a decline in equipment sales, resulting in a 7.8% year-on-year increase in overseas sales. - FY2018AdvancedAnnual report
「In overseas sales, equipment sales were nearly flat, as increases in the urinalysis field were offset by declines mainly in the hematology and blood coagulation testing fields. Reagent sales grew mainly in the hematology, blood coagulation testing and immunochemistry testing fields, and the Group's overseas sales totaled ¥236,915 million, up 14.8% from the previous fiscal year, accounting for 84.0% of sales, up 1.4 percentage points from the previous fiscal year.」
In overseas sales, equipment sales declined in some fields, while reagent sales grew in the hematology, blood coagulation testing and immunochemistry fields, resulting in a 14.8% increase in overseas sales from the previous fiscal year. - FY2018-Q3AdvancedAnnual report
「In overseas sales, equipment sales declined, mainly because of lower equipment sales in the blood coagulation testing field in China, but reagent sales grew mainly in the hematology and blood coagulation testing fields. As a result, the Group's overseas sales totaled ¥170,300 million, up 13.6% year on year, accounting for 84.1% of sales, up 1.2 percentage points year on year.」
In overseas sales, equipment sales declined, while reagent sales grew mainly in the hematology and blood coagulation testing fields, resulting in a 13.6% year-on-year increase in overseas sales. - FY2018-Q2AdvancedAnnual report
「In overseas sales, instrument sales declined mainly in the blood coagulation testing field, while reagent sales increased in the hematology and blood coagulation testing fields. As a result, overseas sales were ¥109,951 million, up 12.4% year on year, and accounted for 83.9% of sales, up 1.6 percentage points year on year.」
The company discloses concrete results related to overseas sales initiatives, including growth in reagent sales in the hematology and blood coagulation testing fields and a 12.4% year-on-year increase in cumulative second-quarter overseas sales. - FY2018-Q1AdvancedAnnual report
「In overseas sales, reagent sales grew in the hematology, urinalysis and immunochemistry testing fields as the number of installed instruments increased. As a result, the Group's overseas sales totaled ¥52,325 million, up 4.7% year on year, accounting for 84.8% of sales, up 0.4 percentage points year on year.」
The company discloses concrete results, including growth in reagent sales as the number of installed instruments increased and a 4.7% year-on-year increase in overseas sales. - FY2017AdvancedAnnual report
「The purpose of the acquisition is to strengthen the sales and service network in Taiwan, expand into new business fields such as immunochemistry testing in addition to hematology testing, and achieve further business growth.」
The company acquired the Taiwan distributor's business on 2 May 2017 and disclosed concrete progress in strengthening its sales and service network and expanding into immunochemistry testing and other fields. - FY2017-Q3RestatedAnnual report
「In overseas sales, equipment sales increased in the hematology and blood coagulation testing fields, while reagent sales grew as the number of installed instruments increased. Performance was solid on a local-currency basis in each country.」
The company reiterates existing initiatives to strengthen its sales and service network and propose solutions, explaining that equipment and reagent sales remained solid on a local-currency basis in each country. - FY2017-Q2AdvancedAnnual report
「In overseas sales, as we strengthened our sales and service network and advanced solution proposals, equipment sales grew mainly in the hematology and blood coagulation testing fields. In addition, reagent sales increased as the number of installed instruments grew, and performance was generally favorable on a local-currency basis in each country.」
The company discloses growth in equipment and reagent sales as a result of existing initiatives. On a consolidated basis, however, overseas sales declined due to yen appreciation. - FY2017-Q1RestatedAnnual report
「In overseas sales, as we strengthened our sales and service network and advanced solution proposals, equipment sales grew mainly in the hematology and blood coagulation testing fields. In addition, reagent sales increased in the immunochemistry testing field as the number of installed instruments grew. As a result, the Group's overseas sales totaled ¥49,965 million, up 0.2% year on year, accounting for 84.4% of sales, down 2.1 percentage points year on year.」
The company continues to describe efforts to strengthen its sales and service network and propose solutions. - FY2016First statedAnnual report
「In overseas sales, as we strengthened our sales and service network and advanced solution proposals, sales of in-vitro diagnostic equipment grew in the hematology and blood coagulation testing fields. In addition, sales of in-vitro diagnostic reagents increased as the number of installed instruments grew.」
The company identifies strengthening its sales and service network and proposing solutions as measures to expand overseas sales.